Why FENC rose 33% since Nov 6
Up 33% from Nov 6 to Nov 20 while the S&P 500 fell 6%.
- Fennec Pharmaceuticals rose 33% from Nov 6 to Nov 20 while biotech stocks fell a median 9%:
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 33% from Nov 6 to Nov 20 while the S&P 500 fell 6%.
| The company | Sales up 71% on the year |
| Latest filing | 10-Q, Nov 12 |
After its last 4 reports it closed +10.9% on average, higher 4 of 4 times.
Above Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. FENC scores 13 today, against a median of 7 over its last 20 recorded sessions.
FENC is #16 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 16 |
Expected to report Tue Mar 23, before the open (in 122 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | +0.8% | +2.4% | +25.3% |
| May 14, 2026 | +6.3% | +36.5% | +44.0% |
| Mar 24, 2026 | -1.5% | +2.5% | +2.2% |
Sales grew in three of the last six years, to $44.6M in 2025. It lost money in each of the eight years.
RSI 66.0, MACD above signal, above both averages. Not scored.
One insider sold $146K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: FENC is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
“The biotechnology and pharmaceutical industries are extremely competitive.”
FENC scores 13 today, which Breakaway calls Above Average. It is #16 of 273 in Biotech by Quality Score, with 5 of 14 chart checks firing. Up 33% from Nov 6 to Nov 20 while the S&P 500 fell 6%. Shares: 25.9% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
FENC scores 13 today, which Breakaway calls Above Average (11 to 14). That is #16 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind FENC's 13.
One insider sold $146K across 1 filing in the last 6 months. No open-market buys on record. The newest is Pierre Sargis Sayad, Chief Medical Officer, who sold $146K on Aug 31.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.